Nasdaq

Medtronic Receives FDA Approval for Expanded MRI Labeling of InterStim™ SureScan™ MRI Leads

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...
BioWorld

Medtronic’s next-gen Interstim X system wins FDA nod

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
Nasdaq

Medtronic Receives CE Mark for InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads

Full-Body MRI-Conditional InterStim II and InterStim Micro Systems Offer Lifestyle-Friendly Choices in Sacral Neuromodulation Therapy to Europeans Suffering from Incontinence InterStim Micro is a ...
MD&M East

Medtronic Ups Its Game in Sacral Neuromodulation for Bowel and Bladder Control

Medtronic and Axonics have been going toe-to-toe in sacral neuromodulation — a fast-growing market that was monopolized by Medtronic until September 2019 — and the incumbent may have just gained the ...
Healio

FDA approves expanded labeling for sacral neuromodulation systems with SureScan MRI leads

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...
MD&M East

Brace Yourself for a More Competitive Medtronic

Medtronic is "finding a new gear," and becoming a more nimble and competitive organization, according to CEO Geoff Martha. "And in the coming weeks, you're going to hear more from me on this topic, as ...